Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
American healthcare workers are making a significant move to Canada, driven by political instability in the U.S. and the allure of a progressive health system.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.